ATE110744T1 - Fibroblast-wachstumsfaktor. - Google Patents

Fibroblast-wachstumsfaktor.

Info

Publication number
ATE110744T1
ATE110744T1 AT86904536T AT86904536T ATE110744T1 AT E110744 T1 ATE110744 T1 AT E110744T1 AT 86904536 T AT86904536 T AT 86904536T AT 86904536 T AT86904536 T AT 86904536T AT E110744 T1 ATE110744 T1 AT E110744T1
Authority
AT
Austria
Prior art keywords
bfgf
growth factor
fibroblast growth
amino acid
acid residue
Prior art date
Application number
AT86904536T
Other languages
English (en)
Inventor
Frederick Stephen Esch
Andrew Baird
Peter Bohlen
Denis Jersy Gospodarowicz
Nicholas Chai-Kwan Ling
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25003873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE110744(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Application granted granted Critical
Publication of ATE110744T1 publication Critical patent/ATE110744T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • C07K14/503Fibroblast growth factor [FGF] basic FGF [bFGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/839Nerves; brain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT86904536T 1985-06-20 1986-06-18 Fibroblast-wachstumsfaktor. ATE110744T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/747,154 US4956455A (en) 1984-03-05 1985-06-20 Bovine fibroblast growth factor

Publications (1)

Publication Number Publication Date
ATE110744T1 true ATE110744T1 (de) 1994-09-15

Family

ID=25003873

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86904536T ATE110744T1 (de) 1985-06-20 1986-06-18 Fibroblast-wachstumsfaktor.

Country Status (7)

Country Link
US (1) US4956455A (de)
EP (2) EP0228449B1 (de)
JP (1) JPH0829097B2 (de)
AT (1) ATE110744T1 (de)
CA (1) CA1341638C (de)
DE (1) DE3650055T2 (de)
WO (1) WO1986007595A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235042A (en) * 1984-02-29 1993-08-10 The Children's Medical Center Corporation Endothelial cell growth factor
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US5604293A (en) * 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
WO1989000198A1 (en) * 1987-07-07 1989-01-12 Biotechnology Research Associates, J.V. Recombinant fibroblast growth factors
DE3650774T2 (de) * 1985-09-12 2003-05-28 Scios Inc Rekombinante Fibroblasten-Wachstums-Faktoren
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
US5439818A (en) * 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
US5026839A (en) * 1985-12-17 1991-06-25 Synergen, Inc DNA encoding a basic fibroblast growth factor
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
US5853988A (en) * 1986-08-11 1998-12-29 Massachusetts Eye And Ear Infirmary Diagnosis of retinoblastoma
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
AU1185488A (en) * 1987-01-16 1988-08-10 Amgen, Inc. Production of fibroblast growth factor
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン,dnaおよびその用途
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
US5750659A (en) * 1987-06-16 1998-05-12 New York University Mammalian growth factor
US5459250A (en) 1987-06-16 1995-10-17 New York University Truncated mammalian growth factor DNA sequence
DE3721081A1 (de) * 1987-06-26 1989-01-19 Progen Biotechnik Gmbh Dna-sequenz, die codiert fuer ein zellteilungsfoerderndes polypeptid, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses polypeptids
KR890701607A (ko) * 1987-11-24 1989-12-21 원본미기재 섬유아세포 성장 인자의 유사체
EP0339905A3 (de) * 1988-04-25 1991-05-08 Ethicon, Inc. Wachstumfaktoren und Retinoiden enthaltende Wundheilungzusammensetzungen
US5126323A (en) * 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
GB9017008D0 (en) * 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
DK0486862T3 (da) * 1990-11-23 1996-06-24 American Cyanamid Co Kimær fibrolast-vækstfaktor
WO1992011872A1 (en) * 1991-01-03 1992-07-23 The Salk Institute For Biological Studies Mitotoxin for treatment of vascular injury
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5492894A (en) * 1991-03-21 1996-02-20 The Procter & Gamble Company Compositions for treating wrinkles comprising a peptide
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
DE4132005A1 (de) * 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
HUT67217A (en) * 1992-02-14 1995-03-28 Kaken Pharma Co Ltd Remedy for airway diseases
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
KR100374310B1 (ko) * 1995-02-14 2003-05-22 주식회사 엘지생명과학 변형된인간염기성섬유아세포성장인자및이의생산방법
CA2217301A1 (en) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Fibroblast growth factor 15
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
CA2339330A1 (en) * 1998-08-13 2000-02-24 University Of Southern California Methods to increase blood flow to ischemic tissue
ATE434440T1 (de) 1998-09-03 2009-07-15 Novartis Vaccines & Diagnostic Fgf-2 angiogenische wirksame einheitdosis und verfahren zu ihrer verwendung
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US6451303B1 (en) * 1998-10-13 2002-09-17 Chiron Corporation Method of treating coronary artery disease by administering a recombinant FGF
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US8618052B2 (en) 1998-10-13 2013-12-31 Novartis Vaccines And Diagnostics, Inc. Method of treating coronary artery disease by administering FGF-5
AU6634400A (en) * 1999-08-13 2001-03-13 Chiron Corporation Dose of an angiogenic factor and method of administering to improve myocardial blood flow
WO2002059278A2 (en) * 2001-01-24 2002-08-01 The Government Of The United States Of America, As Represented By The Secretary Of Department Of Health & Human Services Differentiation of stem cells to pancreatic endocrine cells
US20030211605A1 (en) * 2001-05-01 2003-11-13 Lee Sang-Hun Derivation of midbrain dopaminergic neurons from embryonic stem cells
SI1541674T1 (sl) 2002-06-18 2011-04-29 Eisai R&D Man Co Ltd Primarno kultivirani adipociti za gensko terapijo
AU2004313245B2 (en) 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
CA2695321A1 (en) 2007-08-16 2009-02-26 Andreas Androutsellis-Theotokis Methods for promoting stem cell proliferation and survival
CA2723276A1 (en) * 2008-05-02 2009-11-05 University Of Western Ontario Fgf-9 and its use relating to blood vessels
CA2899865C (en) 2013-02-01 2023-10-10 Kapil BHARTI Method for generating retinal pigment epithelium (rpe) cells from induced pluripotent stem cells (ipscs)
US11530388B2 (en) 2017-02-14 2022-12-20 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of engineering human induced pluripotent stem cells to produce liver tissue
CN113226387B (zh) 2018-11-19 2024-02-23 美国政府(由卫生和人类服务部的部长所代表) 可生物降解的组织置换植入物及其用途
WO2022251499A1 (en) 2021-05-28 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to generate macular, central and peripheral retinal pigment epithelial cells
WO2022251477A1 (en) 2021-05-28 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650774T2 (de) * 1985-09-12 2003-05-28 Scios Inc Rekombinante Fibroblasten-Wachstums-Faktoren
EP0241830A3 (en) * 1986-04-08 1990-01-10 The General Hospital Corporation Hepatoma-derived growth factor
DE4213967A1 (de) * 1992-04-29 1993-11-04 Basf Ag Waessrige polymerisatdispersion

Also Published As

Publication number Publication date
EP0228449A4 (de) 1989-04-24
CA1341638C (en) 2014-06-17
JPH0829097B2 (ja) 1996-03-27
DE3650055D1 (de) 1994-10-06
JPS63500036A (ja) 1988-01-07
EP0228449B1 (de) 1994-08-31
EP0228449A1 (de) 1987-07-15
DE3650055T2 (de) 1994-12-15
US4956455A (en) 1990-09-11
EP0597827A1 (de) 1994-05-18
WO1986007595A1 (en) 1986-12-31

Similar Documents

Publication Publication Date Title
DE3650055T2 (de) Fibroblast-wachstumsfaktor.
NO174351C (no) Fremgangsmåte for fremstilling av human insulinforlöper samt DNA-sekvens og vektor til anvendelse av fremgangsmåten
YU47735B (sh) Postupak za sintezu biološki aktivnih polipeptida limfotoksina
ES8800049A1 (es) Un metodo para la preparacion de eritropoyetina.
ES8704974A1 (es) Procedimiento para la obtencion de derivados de oligopeptido, de efecto tensioactivo compatible con la piel
DE3479734D1 (en) Novel, physiologically active polypeptides and production method thereof
EP0326490A3 (en) Synthetic peptides and mixtures thereof for detecting hiv antibodies
NO175872C (no) Plasmidvektor, fremgangsmåte for fremstilling av peptider og myelomcelle
AU6707686A (en) Prostate-derived growth factor
DK0571475T3 (da) Beta-1,4-galactanase og en DNA-sekvens
EP0249412A3 (en) C-terminal alpha-amidating enzyme and process for production and use thereof
IE810114L (en) N-benzyloxycarbonyl-l-aspartic acid
ATE78872T1 (de) Herstellung von polypeptiden.
JPS6420086A (en) Polypeptide and production thereof
GR3007491T3 (de)
DE3686981D1 (de) Produktion eines proteins.
ES8801378A1 (es) Un metodo para preparar un vector de expresion que tiene un sistema de replicacion funcional en un microorganismo hospedante
DK157902C (da) Hoejkoncentrerede, vandige aminoxidpraeparater og fremgangsmaade til fremstilling heraf
EP0687685A4 (de) Physiologisch-aktive peptide
PT84011A (fr) Procede de preparation de nouveaux analogues de composes polypeptidiques hypocalcemiants epargnant de calcium de l:organisme
TW243453B (en) Cloning and characterization of a cardiac adenylyl cyclase
ES8603380A1 (es) Un procedimiento para producir cristales de sal equimolar delirina y acido 2-hidroxi-4-metiltiobutirico
ES2000879A6 (es) Un procedimiento para preparar una sal de acido inorganico de cloruro de n-(1(s)-etoxicarbonil-3-fenilpropil)-l-alanilo
ATE52258T1 (de) Verfahren zur herstellung von 2-beta-dribofuranosylselenazol-4-carboxamid.
IL76150A (en) Derivatives of aminochromancarboxylic acid and their preparation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time